Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CENTERSTONE: Baloxavir to Reduce Household Influenza Transmission
NCT03969212Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing Baloxavir Marboxil with Placebo (2 arms). Primary endpoint: Percentage of HHCs With Virological Influenza Transmission by Day 5. Started Oct 2019; status: completed.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03969212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969212.